STAGE 2: RCT
Glasgow Royal Infirmary are the current RCT top recruiters with Basildon,Glasgow RAH, Bristol and The Royal London Hospital following closely behind.
STAGE 1: feasibility study
As a University, UCL uses personally-identifiable information to conduct research to improve health, care and services. As a publicly-funded organisation, we have to ensure that it is in the public interest when we use personally-identifiable information from people who have agreed to take part in research. This means that when you agree to take part in a research study, we will use your data in the ways needed to conduct and analyse the research study. Your rights to access, change or move your information are limited, as we need to manage your information in specific ways in order for the research to be reliable and accurate. If you withdraw from the study, we will keep the information about you that we have already obtained. To safeguard your rights, we will use the minimum personally-identifiable information possible.
Health and care research should serve the public interest, which means that we have to demonstrate that our research serves the interests of society as a whole. We do this by following the UK Policy Framework for Health and Social Care Research. If you wish to raise a complaint on how we have handled your personal data, you can contact the trial team who will investigate the matter. If you are not satisfied with our response or believe we are processing your personal data in a way that is not lawful you can complain to the Information Commissioner’s Office (ICO).
The ATTIRE team can be conducted on email@example.com
This website has been designed and produced for use by Healthcare Professionals involved in the ATTIRE Trial. Patients: please discuss questions with the Doctor responsible for your care
ATTIRE is funded via the HIC fund
This is a parallel funding partnership between the Wellcome Trust and the Department of Health to stimulate the creation of innovative healthcare products, technologies and interventions and to facilitate their development for the benefit of patients in the NHS and beyond.
ATTIRE aims to evaluate the re purposing of 20% Human Albumin Solution to prevent infection and augment the treatment of infection in acutely decompensated cirrhosis.
The Comprehensive Clinical Trials Unit at UCL will design, conduct, analyse and report high quality clinical trials and other well designed studies that fit with the research strategies of UCL and UCL Partners.
A trial to determine whether targeting a near normal serum level of albumin (35g/l) in patients admitted with acute decompensation of cirrhosis by repeated infusion of 20% human albumin solution throughout admission (maximum of 14 days) will lessen organ dysfunction, reduce nosocomial infections and improve mortality compared to standard of care.